Light at night activates IGF-1R/PDK1 signaling and accelerates tumor growth in human breast cancer xenografts

Cancer Research

Volumn 71, Issue 7, 2011, Pages 2622-2631

  Wu, Jinghai ^a   Dauchy, Robert T ^c   Tirrell, Paul C ^a   Wu, Steven S ^a   Lynch, Darin T ^a   Jitawatanarat, Potjana ^b   Burrington, Christine M ^a   Dauchy, Erin M ^c   Blask, David E ^c   Greene, Michael W ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b BASSETT HEALTHCARE   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CELL PROLIFERATION; CIRCADIAN RHYTHM; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIGHT; NIGHT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CIRCADIAN RHYTHM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIGHT; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, NUDE; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79953296650     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3837     Document Type: Article

References (50)

1. Hastings MH, Reddy AB, Maywood ES. A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 2003;4:649-61. (Pubitemid 37280160)
2. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat Rev Genet 2008;9:764-75.
3. Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 2001;12:279-87. (Pubitemid 32515375)
4. Blask DE, Dauchy RT, Brainard GC, Hanifin JP. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women. Integr Cancer Ther 2009;8:347-53.
5. Reiter RJ, Tan DX, Erren TC, Fuentes-Broto L, Paredes SD. Light-mediated perturbations of circadian timing and cancer risk: a mechanistic analysis. Integr Cancer Ther 2009;8:354-60.
6. Rajaratnam SM, Arendt J. Health in a 24-h society. Lancet 2001;358:999-1005. (Pubitemid 32913531)
7. Sigurdson K, Ayas NT. The public health and safety consequences of sleep disorders. Can J Physiol Pharmacol 2007;85:179-83. (Pubitemid 46996117)
8. Straif K, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol 2007;8:1065-6.
9. Hansen J. Increased breast cancer risk among women who work predominantly at night. Epidemiology 2001;12:74-7. (Pubitemid 32006465)
10. Schernhammer ES, Kroenke CH, Laden F, Hankinson SE. Night work and risk of breast cancer. Epidemiology 2006;17:108-11.
11. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst 2003;95:825-8. (Pubitemid 36798430)
12. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res 2007;67:10618-22. (Pubitemid 350070839)
13. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol 2006;164:549-55. (Pubitemid 44412783)
14. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28.
15. Werner H, Le Roith D. New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia. Cell Mol Life Sci 2000;57:932-42. (Pubitemid 30461834)
16. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009;27:176-85.
17. Lopez T, Hanahan D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 2002;1:339-53. (Pubitemid 41039136)
18. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003;63:4384-8. (Pubitemid 36951007)
19. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L. Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 2001;18:709-27. (Pubitemid 32929215)
20. Nakamura K, Sakaue H, Nishizawa A, Matsuki Y, Gomi H, Watanabe E, et al. PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27Kip1 expression. J Biol Chem 2008;283:17702-11.
21. Toker A, Newton AC. Cellular signaling: pivoting around PDK-1. Cell 2000;103:185-8.
22. Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A. 3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway. Mol Cancer Res 2010;8:421-32.
23. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI. 3-phosphoinositide- dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 2006;6:77.
24. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-9. (Pubitemid 47105993)
25. Hotte SJ, Oza A, Winquist EW, Moore M, Chen EX, Brown S, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann Oncol 2006;17:334-40. (Pubitemid 43160126)
26. Maga G, Blanca G, Shevelev I, Frouin I, Ramadan K, Spadari S, et al. The human DNA polymerase lambda interacts with PCNA through a domain important for DNA primer binding and the interaction is inhibited by p21/WAF1/CIP1. FASEB J 2004;18:1743-5. (Pubitemid 39561670)
27. Dauchy RT, Sauer LA. Preparation of "tissue-isolated" rat tumors for perfusion: a new surgical technique that preserves continuous blood flow. Lab Anim Sci 1986;36:678-81.
28. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, Krause JA, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84. (Pubitemid 41713389)
29. Sauer LA, Stayman JW 3rd, Dauchy RT. Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res 1982;42:4090-7. (Pubitemid 13198570)
30. Sauer LA, Dauchy RT, Blask DE, Armstrong BJ, Scalici S. 13-Hydroxyoctadecadienoic acid is the mitogenic signal for linoleic aciddependent growth in rat hepatoma 7288CTC in vivo. Cancer Res 1999;59:4688-92. (Pubitemid 29428977)
31. Wu J, Lingrel JB. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene 2004;23:8088-96. (Pubitemid 39531849)
32. Dauchy RT, Blask DE, Sauer LA, Brainard GC, Krause JA. Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 1999;144:131-6. (Pubitemid 29457654)
33. Balendran A, Hare GR, Kieloch A, Williams MR, Alessi DR. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 2000;484:217-23.
34. Copps KD, Hancer NJ, Opare-Ado L, Qiu W, Walsh C, White MF. Irs1 serine 307 promotes insulin sensitivity in mice. Cell Metab 11;84-92.
35. Hunt T, Sassone-Corsi P. Riding tandem: circadian clocks and the cell cycle. Cell 2007;129:461-4. (Pubitemid 46660976)
36. Walisser JA, Bradfield CA. A time to divide: does the circadian clock control cell cycle? Dev Cell 2006;10:539-40.
37. Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, et al. Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res 2010;70:3351-60.
38. Baserga R. Growth regulation of the PCNA gene. J Cell Sci 1991;98(Pt 4):433-6.
39. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol 2006;8:1359-68. (Pubitemid 44835110)
40. de Vente JE, Kukoly CA, Bryant WO, Posekany KJ, Chen J, Fletcher DJ, et al. Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. J Clin Invest 1995;96:1874-86.
41. Sun XG, Rotenberg SA. Overexpression of protein kinase Calpha in MCF-10A human breast cells engenders dramatic alterations in morphology, proliferation, and motility. Cell Growth Differ 1999;10:343-52. (Pubitemid 29242600)
42. Hara T, Saito Y, Hirai T, Nakamura K, Nakao K, Katsuki M, et al. Deficiency of protein kinase Calpha in mice results in impairment of epidermal hyperplasia and enhancement of tumor formation in twostage skin carcinogenesis. Cancer Res 2005;65:7356-62. (Pubitemid 41161268)
43. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46.
44. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, et al. 3- Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009;69:6299-306.
45. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009;16:21-32.
46. Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008;30:203-13. (Pubitemid 351626686)
47. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J 2002;21:3728-38. (Pubitemid 34787046)
48. Lopez-Bergami P, Kim H, Dewing A, Goydos J, Aaronson S, Ronai Z. c-Jun regulates phosphoinositide-dependent kinase 1 transcription: implication for Akt and protein kinase C activities and melanoma tumorigenesis. J Biol Chem 2010;285:903-13.
49. Peifer C, Alessi DR. New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen. Biochem J 2009;417:e5-7.
50. Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res 2002;62:3538-43. (Pubitemid 34651405)